TP53 mutations, found in approximately 50–60% of muscle-invasive or high-risk bladder cancers, impair DNA repair and cell cycle regulation, correlating with aggressive phenotypes and poor prognosis [12, 14]. This evidence concerns the gene TP53 and urinary bladder cancer.